[News] Carfilzomib for multiple myeloma
01:01 EDT 3 Aug 2012 | The Lancet
Carfilzomib, a next-generation proteasome inhibitor, could help treat patients with relapsed and refractory multiple myeloma, according to the findings of a phase 2b study. The open-label, single-arm study reported in Blood involved 266 patients (me..
Original Article: [News] Carfilzomib for multiple myeloma
More From BioPortfolio on "[News] Carfilzomib for multiple myeloma"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
